The U.S. Food and Drug Administration announced on October 14, 2026 the launch of the Rare Disease Framework Initiative, an effort to build a more tailored regulatory approach to developing drugs and biologics for rare diseases, according to the official release. The agency, part of the U.S. Department of Health and Human Services, said the effort begins with a public feedback meeting scheduled for October 28 at its White Oak campus.
Key takeaways
- The FDA announced on October 14, 2026 a new Rare Disease Framework Initiative aimed at creating a tailored, fit-for-purpose regulatory approach for rare disease drug development.
- The agency says only about 5% of rare conditions currently have an FDA-approved treatment.
- A public meeting to gather feedback will be held October 28 at the FDA's White Oak campus, facilitated by the Reagan-Udall Foundation for the FDA.
- The initiative is led by the FDA's Rare Disease Innovation Hub along with the Office of the Commissioner, CBER and CDER, and could eventually lead to new guidance, regulatory changes, training and organizational shifts.
What the FDA Announced
The FDA said the Rare Disease Framework Initiative is intended to reimagine how drugs and biologics for rare diseases are developed and reviewed, moving away from a one-size-fits-all regulatory model. The agency released a white paper alongside the announcement laying out plans for what it calls an 'optimized, fit-for-purpose framework' that accounts for the nuances of each disease, patient needs, product type, and the evidence that can realistically be generated in small patient populations.
HHS Secretary Robert F. Kennedy, Jr. said, 'Americans with rare diseases cannot afford a regulatory system that treats every condition the same,' adding that under President Trump the FDA is 'rethinking rare disease drug development by putting patients at the center and matching regulatory requirements to the realities of small patient populations.' Acting FDA Commissioner Kyle Diamantas said the agency will build 'a more consistent, predictable, and innovative approach to rare disease drug development while maintaining the rigorous standards Americans expect from the FDA.'
The initiative is led by the FDA's Rare Disease Innovation Hub, working with the Office of the Commissioner, the Center for Biologics Evaluation and Research (CBER), and the Center for Drug Evaluation and Research (CDER), according to the agency.
The Numbers Behind the Initiative
The FDA said the push for a new framework comes despite years of existing regulatory flexibility and targeted programs supporting rare disease drug development, which the agency credits with 'meaningful advances for patients and families.' Even so, the agency stated that only about 5% of rare conditions have an FDA-approved treatment, a figure it cited as evidence that 'more must be done to speed the development of safe and effective treatments for rare diseases.'
The release did not provide a comparison figure from a prior year or a historical baseline against which to measure progress, nor did it specify how many rare diseases exist in total or how many treatments have been approved to date. The table below summarizes the specific figures and dates included in the announcement.
Key Figures From the Announcement
| Measure | Latest figure | Comparison figure | Change |
|---|---|---|---|
| Rare conditions with an FDA-approved treatment | ~5% | Not stated | Not stated |
| Initiative announcement date | October 14, 2026 | Not stated | Not stated |
| Public feedback meeting date | October 28, 2026 | Not stated | Not stated |
How the Public Feedback Process Will Work
The FDA said it will solicit feedback on the initiative from patients and disease advocates, industry, and other stakeholders beginning with the October 28 meeting at its White Oak campus, which will be facilitated by the Reagan-Udall Foundation for the FDA, an independent nonprofit that supports FDA's regulatory science mission. The agency said further opportunities for input will follow, including sector-specific roundtables, formal Requests for Information, and internal FDA feedback sessions.
According to the release, this feedback will inform the detailed development of the new framework, which 'might include potential new or revised guidance, revisions to regulations, staff training, and organizational changes.' The FDA listed six specific commitments guiding the framework's development, including providing greater clarity and predictability in regulatory decision-making, embedding patient input earlier in the drug development and review process, leveraging external expertise, building shared training and institutional knowledge, applying risk-based approaches to chemistry, manufacturing and controls review and pre-approval inspections, and championing cutting-edge science and novel statistical methods.
Amy Comstock Rick, Director of the FDA's Rare Disease Innovation Hub, said in the release that 'a bold vision to reimagine the framework for rare disease drug development that builds on key learnings and milestones is necessary to meet this moment,' adding that the new framework 'will enhance consistency and predictability for both sponsors and for patients.'
The FDA's Broader Regulatory Role
The FDA, an agency within HHS, is responsible for assuring the safety, effectiveness and security of human and veterinary drugs, vaccines and other biological products, as well as medical devices, food, cosmetics, dietary supplements, and tobacco products. Rare disease drug development typically faces unique scientific and regulatory challenges because small patient populations make it harder to generate the large-scale clinical trial data normally expected for approval, which is part of why the agency has historically used flexible pathways and designations for these conditions.
This initiative builds on that existing flexibility rather than replacing it outright, with the FDA framing the new framework as an effort to formalize and expand tailored review practices across the agency's drug and biologic review centers. The process outlined in the release — a public meeting followed by roundtables, Requests for Information, and internal review — mirrors how the FDA has previously developed other major guidance efforts, such as its recent work on when prescription drug apps require agency review, where public input shaped the final regulatory approach. Separately, the agency continues to issue individual drug approvals in the meantime, including its recent clearance of a new antisense drug for chronic hepatitis B.
Frequently asked questions
When is the FDA's public meeting on the Rare Disease Framework Initiative?
The FDA said the meeting will take place October 28 at its White Oak campus, facilitated by the Reagan-Udall Foundation for the FDA. It is intended to gather feedback from patients, disease advocates, industry and other stakeholders.
Who will be affected by this new framework?
The initiative is aimed at patients and families living with rare diseases, drug and biologic developers, and FDA review staff, since it is meant to change how rare disease treatments are developed and evaluated for approval.
What happens after the October 28 meeting?
The FDA said further opportunities for input will follow, including sector-specific roundtables, Requests for Information, and internal FDA feedback sessions, which will inform development of a framework that could include new or revised guidance, regulatory changes, staff training, and organizational changes.